Riskpilot← Back to searchSign inGet full accessS.E Urology AB
ABActiveOrg 5591103667Augustenborgsgatan 23 AMedical specialists activities · NACE 8622Est. 20171 employees
Revenue 2025
SEK 1,3M
+28% vs 2024
EBITDA margin
30.3%
+240% vs 2024
Equity ratio
86.8%
Financial strength
Net profit 2025
SEK 307K
+262% vs 2024
| Revenue | SEK 1,3M | +28% |
| EBITDA | SEK 391K | +240% |
| Net profit | SEK 307K | +262% |
| Total assets | SEK 2,3M | -3% |
| Equity | SEK 2M | -5% |
| Employees | 1 | — |
Legal name
S.E Urology AB
Org number
5591103667
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
28 april 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsultverksamhet i öppen och sluten vård, utbildning och handledning och förvaltning av fast egendom och värdepapper, kapitalförvaltning samt därmed förenlig verksamhet.
Address
Augustenborgsgatan 23 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 475 | 1 684 | 1 189 | 1 010 | 1 289 |
| Staff expenses | — | −739 | −606 | −776 | −722 |
| EBITDA | 655 | 742 | 327 | 115 | 391 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 655 | 742 | 327 | 115 | 391 |
| Net financials | −1 | −1 | −1 | −6 | −3 |
| Profit before tax | 654 | 741 | 326 | 109 | 388 |
| Tax | −135 | −153 | −67 | −24 | −81 |
| Net profit | 519 | 588 | 258 | 85 | 307 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 855 | 2 419 | 2 419 | 2 361 | 2 295 |
| Equity | 1 566 | 1 954 | 2 018 | 2 103 | 1 992 |
| Long-term debt | 0 | 27 | 28 | 33 | 48 |
| Short-term debt | 289 | 437 | 373 | 225 | 255 |
| Total debt | 289 | 465 | 401 | 258 | 303 |
EBITDA margin
30.3%
This company
15.8%
Market median
+92% vs market
20212025
Equity ratio
86.8%
This company
38.2%
Market median
+127% vs market
20212025
Return on equity
15.4%
This company
18.4%
Market median
+16% vs market
20212025
Net profit margin
23.8%
This company
8.1%
Market median
+194% vs market
20212025
Asset turnover
0.56×
This company
1.12×
Market median
-50% vs market
20212025
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of S.E Urology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Saad El Zanati | Board of Directors | 0 companies |
| Inger Marianne Nerman | Deputy Board Member | 0 companies |
| Haci Bilal Atac | Deputy Board Member | 0 companies |